FDA cancels meeting to discuss Neurocrine's Ingrezza

FDA cancelled a planned meeting of its Psychopharmacologic Drugs Advisory Committee to discuss an NDA for Ingrezza valbenazine from Neurocrine Biosciences Inc. (NASDAQ:NBIX) to treat tardive dyskinesia. The meeting was scheduled for Feb. 16.

The compound is under Priority Review, with an April 11 PDUFA date. Neurocrine said the review will continue as planned (see BioCentury Extra, Oct. 11, 2016)...